Many cancer-associated mutational signatures remain unexplained. Team CAUSE aims to connect DNA damage, mutational patterns, ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results